Skip to main content
Premium Trial:

Request an Annual Quote

DermTech: Michael Howell

DermTech has appointed Michael Howell as CSO, a role in which he will coordinate research, new product development, and clinical validation efforts. Howell has over twenty years of academic and pharmaceutical industry experience. Prior to joining DermTech, he was the translational research lead for inflammation and autoimmunity at Incyte, driving the strategic expansion of Incyte’s pipeline in dermatology and other immunological disorders. Prior to that, he held various other roles within the pharmaceutical industry at Boehringer Ingelheim, Immune Tolerance Network, and MedImmune/AstraZeneca. Howell also served as a faculty member in the Division of Allergy and Immunology at National Jewish Health. He earned a bachelor of science degree in biology from Messiah College and a doctorate in immunology from West Virginia University School of Medicine.
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.